文章核心观点 - 公司BDC-1001的免疫刺激抗体偶联物(ISAC)针对人表皮生长因子受体2(HER2)抗原,效果不如公司向投资者表述的那样,很可能无法达到预定的成功标准 [1][5] - 因此,公司夸大了产品管线的临床和商业前景,这是公司维持其业务模式的主要依赖 [5] - 上述情况使公司面临高风险的管理层变动和大规模裁员 [5] - 当真实情况被披露时,投资者遭受损失 [5] 根据相关目录分别进行总结 公司概况 - 公司名称为Bolt Biotherapeutics, Inc. [1] - 公司股票代码为NASDAQ: BOLT [1] - 公司主要从事免疫刺激抗体偶联物(ISAC)的研发,其中BDC-1001针对HER2抗原 [5] 诉讼情况 - 公司在2021年2月5日至2024年5月14日期间(包括两个日期)的证券交易遭到集体诉讼 [1] - 原告要求在2024年9月3日之前指定首席原告代表集体利益进行诉讼 [1][3] - 原告律师事务所为Rosen Law Firm,声称拥有丰富的证券集体诉讼经验 [4] 指控内容 - 公司对BDC-1001的临床和商业前景做出了虚假或误导性陈述 [5] - 公司夸大了产品管线的前景,这是公司维持业务模式的主要依赖 [5] - 上述情况使公司面临高风险的管理层变动和大规模裁员 [5] - 当真实情况被披露时,投资者遭受损失 [5]

If you are a shareholder who suffered a loss, click here to participate. LOS ANGELES, July 24, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ: BOLT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. CONTACT: The Schall Law Firm Brian Schall, Esq. ...

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The complaint alleges that on May 14, 2024, Bolt issued a press release announcing that the Company would cease further development of BDC-1001 and focus resources on BDC-3042 and BDC-4182 upon determining that BDC-1001 failed to meet its pre-defined success criteria, that the Company's Chief Executive Officer Randall C. Schatzman and Chief Medical Officer Edith Perez would be moved into advisory roles ...

SO WHAT: If you purchased Bolt securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) BDC-1001, Bolt's immune-stimulating antibody conjugate ("ISAC") designed to target a tumor antigen known as human epidermal growth factor receptor 2 ("HER2") that is often found in cance ...

公司核心事件 - 公司于2024年5月14日宣布停止主要资产trastuzumab imbotolimod（BDC-1001）的进一步开发并裁员约50% [1] - 公司股价在公告次日下跌0.49美元/股，跌幅达37.12%，收盘价报0.83美元/股 [10] - 多家分析机构随后下调公司股票评级 [1] 法律诉讼指控 - 指控公司及高管违反联邦证券法，发布虚假和/或误导性陈述 [5] - 具体指控包括BDC-1001疗效低于公司向投资者宣传的水平，且实际上未达到预定义成功标准 [5] - 指控公司夸大产品管线的临床和商业前景，导致领导层动荡和大规模裁员风险升高 [5] 投资者法律程序 - 联邦证券集体诉讼的牵头原告申请截止日期为2024年9月3日 [4] - 法院指定牵头原告需为集体成员中具有最大财务利益且符合典型性要求的投资者 [6] - 投资者可选择通过代理律师申请担任牵头原告或保持缺席集体成员身份 [6]

集体诉讼案件 - 罗森律师事务所代表在2021年2月5日至2024年5月14日期间购买Bolt Biotherapeutics Inc (NASDAQ BOLT) 证券的投资者提起集体诉讼 [7] - 诉讼指控公司作出虚假和/或误导性陈述及/或未披露关键信息 包括主要候选药物BDC-1001的疗效低于公司向投资者宣传的水平 [8] - 公司 overstated其产品管线的临床和/或商业前景 这对其业务模式的可持续性至关重要 [8] 公司产品管线 - BDC-1001是一种免疫刺激抗体偶联物(ISAC) 靶向人类表皮生长因子受体2(HER2) 该靶点常见于乳腺癌和胃食管癌等癌症 [8] - 该药物实际上不太可能达到其预定义的成功标准 与公司向投资者的表述存在重大差异 [8] 公司治理与运营影响 - 上述情况使公司面临领导层更迭风险加剧和大幅裁员的高度风险 [8] - 当真实细节进入市场时 投资者遭受了损失 [8] 法律程序进展 - 集体诉讼尚未获得认证 投资者目前除非自行聘请律师 否则没有法律代表 [2] - 首席原告申请截止日期为2024年9月3日 投资者可通过指定网站或电话联系参与诉讼 [1][4] - 投资者无需支付任何自付费用 可通过应急费用安排获得潜在补偿 [3]

NEW YORK, July 13, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of SeaStar Medical Holding Corporation (NASDAQ: ICU) and Bolt Biotherapeutics (NASDAQ: BOLT). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. Class Period: October 31, 2022 - March 26 ...

WHAT TO DO NEXT: To join the Bolt class action, go to https://rosenlegal.com/submit-form/?case_id=26946 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 3, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. DETAILS OF THE CASE: According to ...

To be considered for a lead plaintiff role, a Bolt investor must file a motion in the U.S. District Court for the Northern District of California, no later than September 3, 2024. Please contact Edelson Lechtzin LLP to discuss your investment losses, at 844-696-7492 or by e-mail at [email protected]. You can also submit your trading information online HERE. Background on Bolt Biotherapeutics, Inc. focused on developing immunotherapies for cancer treatment, primarily through its "Boltbody" pipeline. The Bolt ...

[Click here for information about joining the class action] Throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) BDC-1001 was less effective than the Company had represented to investors and was in fact unlikely to meet its pre-defined success criteria; (ii) accordingly, Defendants overstated the clinical and/or c ...